

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI XDC CAYMAN INC.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2268)

**VOLUNTARY ANNOUNCEMENT
PROPOSED ON-MARKET SHARE PURCHASE
FOR THE SHARE SCHEMES OF THE COMPANY**

This announcement is made by WuXi XDC Cayman Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company hereby announces that it has resolved to utilize internal funds of up to US\$100 million for the professional trustee appointed by the Company in respect of the share schemes of the Company from time to time (the “**Share Schemes**”) to purchase the Shares in the open market at the prevailing market price (the “**Proposed Share Purchase**”).

The Company believes that the current trading price of the Shares does not reflect their intrinsic value or the actual business prospects of the Company, which represents a good opportunity for the Company to conduct the Proposed Share Purchase. The Board believes that the Group’s current financial resources would enable it to implement the Proposed Share Purchase with its internal resources while maintaining solid financial position for the continued growth of the Group’s operation.

The Proposed Share Purchase will be conducted in accordance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and other applicable laws and regulations.

By order of the Board
WuXi XDC Cayman Inc.
Dr. Jincan LI

Executive Director and Chief Executive Officer

Hong Kong, May 18, 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincal LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Dr. Jijie GU and Ms. Ming SHI as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.

** For identification purpose only*